Human Metabolome Technologies Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Human Metabolome Technologies için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Life Sciences kazanç büyümesi	26.9%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture

Oct 03

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Aug 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Jun 07

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

May 22

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Apr 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Mar 23

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Feb 26

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Human Metabolome Technologies yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

TSE:6090 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2024	1,384	246	N/A	N/A	N/A
6/30/2024	1,345	243	202	236	N/A
3/31/2024	1,339	285	N/A	N/A	N/A
12/31/2023	1,321	282	134	256	N/A
9/30/2023	1,272	264	N/A	N/A	N/A
6/30/2023	1,299	285	168	284	N/A
3/31/2023	1,288	214	N/A	N/A	N/A
12/31/2022	1,300	259	244	283	N/A
9/30/2022	1,312	298	N/A	N/A	N/A
6/30/2022	1,223	267	178	324	N/A
3/31/2022	1,208	246	N/A	N/A	N/A
12/31/2021	1,120	147	-19	114	N/A
9/30/2021	1,052	46	N/A	N/A	N/A
6/30/2021	1,124	58	-61	-34	N/A
3/31/2021	1,051	-42	N/A	N/A	N/A
12/31/2020	1,201	64	26	68	N/A
9/30/2020	1,165	5	N/A	N/A	N/A
6/30/2020	1,118	-47	150	184	N/A
6/30/2019	839	-469	-334	-212	N/A
3/31/2019	834	-359	-360	-215	N/A
12/31/2018	857	-312	N/A	N/A	N/A
9/30/2018	907	-217	-225	-78	N/A
6/30/2018	971	-151	N/A	N/A	N/A
3/31/2018	938	-156	N/A	-178	N/A
12/31/2017	923	-182	N/A	N/A	N/A
9/30/2017	948	-130	N/A	-54	N/A
6/30/2017	938	-70	N/A	N/A	N/A
3/31/2017	914	-61	N/A	45	N/A
12/31/2016	840	-74	N/A	N/A	N/A
9/30/2016	754	-119	N/A	-43	N/A
6/30/2016	784	-82	N/A	N/A	N/A
3/31/2016	780	-71	N/A	-58	N/A
12/31/2015	783	16	N/A	N/A	N/A
9/30/2015	743	-9	N/A	15	N/A
6/30/2015	684	-57	N/A	N/A	N/A
3/31/2015	686	-34	N/A	66	N/A
12/31/2014	630	-108	N/A	N/A	N/A
9/30/2014	649	-74	N/A	N/A	N/A
6/30/2014	600	-58	N/A	N/A	N/A
3/31/2014	610	1	N/A	29	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 6090 'un tahmini kazanç büyümesinin tasarruf oranının ( 0.3% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: 6090 'un kazançlarının JP pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: 6090 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: 6090 şirketinin gelirinin JP pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: 6090 şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 6090 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Human Metabolome Technologies Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023

Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022

Recent updates

Less than half of directors are independent

Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture

Human Metabolome Technologies, Inc. to Report Q1, 2025 Results on Nov 13, 2024

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Investor sentiment deteriorates as stock falls 21%

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥15.00 per share

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023)

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023)

Dividend of JP¥15.00 announced

Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024

First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023)

Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023

New major risk - Earnings quality

Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022)

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023

Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023

Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022)

Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022

Investor sentiment improved over the past week

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022

Insufficient new directors

Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022

First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021)

Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020)

New 90-day high: JP¥999

Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021

New 90-day low: JP¥741

New 90-day low: JP¥860

Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020

Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin